UNSPSC 51161546: Midaxifylline

This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C16H25N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A937Z0MS6C, chemically known as 8-(1-aminocyclopentyl)-1,3-dipropylxanthine but generally known as midaxifylline, which bears US NIH Compound Identifier 3047747. European Medicines Agency schedules Midaxifylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03288MIG.

UNSPSC 51161546 Midaxifylline, a Commodity code, covers pharmaceutical products being procured through multistate cooperative purchasing vehicles to supply state and local government facilities with generic medications and over-the-counter products. The scope of work encompasses the supply and distribution of pharmaceuticals identified by National Drug Code (NDC), with vendors required to maintain relationships with authorized drug wholesalers, comply with current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) standards, and offer flexible pricing structures including flat price, net price formats, or WAC-minus pricing. Issuing bodies include state procurement offices administering cooperative purchasing alliances that aggregate demand across multiple participating jurisdictions; the Minnesota Department of Administration's Office of State Procurement, through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), serves as a prominent vehicle for this activity, with participating members spanning state and local government facilities across multiple states including Oregon.

Recent activity shows MMCAP issuing a Request for Proposal (S1070000015802) posted January 20, 2026, with a response deadline of March 26, 2026, to establish multiple manufacturer contracts for generic pharmaceuticals and OTC products effective July 1, 2026. The procurement requires vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain comprehensive insurance including $5 million commercial general liability, and meet administrative and performance compliance standards with penalties ranging from $200 to $1,500 per violation. Evaluation criteria weight price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, EDI capability, administrative compliance, and agreement to a 3 percent administrative fee. Contract terms span two years for new vendors with optional extensions, while incumbents' amendments extend through June 30, 2028.